BackBioXcel Therapeutics Overview

BioXcel Therapeutics EBIT

EBIT (Earnings Before Interest and Taxes) analysis for BTAI.

Quarterly EBIT

-$10.22M
40.93% YoY

As of Mar 31, 2026

Annual EBIT (TTM)

-$62.86M
38.37% YoY

Trailing 12 months ending Mar 31, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)